ERITROPOYETINA COMO AGENTE ERITROPOYÉTICO Y NO ERITROPOYÉTICO. CONSIDERACIONES TERAPÉUTICAS

VITTORI, D; CHAMORRO, ME; NESSE, A

ACTA BIOQUíMICA CLíNICA LATINOAMERICANA

FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES

Lugar: La Plata; Año: 2016 vol. 50 p. 773 - 782

0325-2957

Erythropoietin (Epo), the cytokine required for promoting erythropoiesis through the proliferation and differentiation of erythroid cells, has been reported to act as a pleiotropic cytokine beyond the hematopoietic system.In contrast with the potentially beneficial effects attributed to recombinant human erythropoietin (rhuEpo), research has advanced to indicate that mortality and morbidity rates are increased in some patient groups when treated with rhuEpo. Some cardiac and systemicconditions may predispose to adverse events, and other factors, such as proinflammatory agents, may lead to resistance to erythropoietin treatment. Many compounds are currently under investigation in order to avoid these unwanted effects and to reduce the rhuEpo dose during chronic therapies. They are either erythropoiesis-stimulating agents different from erythropoietin or structurally modified erythropoietins with altered properties and activities.In recent reports, contrasting data have raised several concerns regarding the effectiveness of erythropoietin treatment to prevent adverse events. Therefore, much investigation is needed to provide a solid basis for the development of conclusive clinical trials.